# Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

> **NCT02888054** · PHASE1 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** lesinurad/allopurinol 200/300 FDC tablet
- **DRUG:** lesinurad 200 mg
- **DRUG:** allopurinol 300 mg

## Key facts

- **NCT ID:** NCT02888054
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-30
- **Primary completion:** 2016-10-18
- **Final completion:** 2017-02-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02888054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02888054, "Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02888054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*